BRD2 and infection: Existing evidence suggests that treatment with moderate-efficacy first-line DMTs (i.e., IFNβ-1b and GA) modestly increase the risk of infection, whereas high-efficacy second-line DMTs (i.e., NAT and FTY) appear to increase sharply [2].